| Filed | Form | Description | |
|---|---|---|---|
| 8/1/25 | DEFA14A | DEFA14A | → |
| 7/21/25 | DEF 14A | DEF 14A | → |
| 7/11/25 | PRE 14A | PRE 14A | → |
| 5/1/25 | DEFA14A | DEFA14A | → |
| 4/10/25 | DEF 14A | DEF 14A | → |
| 3/14/25 | PRE 14A | PRE 14A | → |
| ↓ | |||
| Filed | Form | Description | |
|---|---|---|---|
| 2/27/26 | 4 | 4 | → |
| 2/27/26 | 4 | 4 | → |
| 1/2/26 | 4 | 4 | → |
| 1/2/26 | 4 | 4 | → |
| 11/5/25 | 4 | 4 | → |
| 10/3/25 | 4 | 4 | → |
| ↓ | |||
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers.